More AIDS patients may get cheaper drugs
(AP) -- Gilead Sciences Inc. will allow some of its AIDS drugs to be made by generic manufacturers, potentially increasing their availability in poor countries, particularly in Africa, officials said Tuesday.
In the first deal of its kind, the pharmaceutical company has agreed to allow four of its AIDS drugs to be made by generic drug companies at a cheaper cost in return for a small proportion of royalties, United Nations health officials said.
Most of the 33 million people worldwide who have HIV, the virus that causes AIDS, live in Africa. One of the drugs will also be used to treat people with hepatitis.
The deal was negotiated by the Medicines Patent Pool, part of a U.N.-led partnership that raises money for AIDS, tuberculosis and malaria by things like taxing airplane tickets. Among the partnership's 29 member countries, only Chile, France, Korea, Mali and Niger are actually implementing the airline tax.
"We will continue to work with Gilead and others to expand access to all people living with HIV in developing countries," said Ellen 't Hoen, executive director of the Medicines Patent Pool.
Gilead will receive from three to five percent royalties on its four drugs, which will be supplied to about 100 countries.
Until now, its drugs have been mainly sold in rich countries, and profits from the new deal are expected to be a tiny fraction of those Gilead gets from the West.
Typically, patients in poor countries have to wait for years until the patents expire on new drugs before they can be made more cheaply by generic companies.
But some experts questioned whether the deal went far enough and pointed out it specifically excludes manufacturers in Thailand and Brazil, which both produce large amounts of generic drugs.
"This agreement is an improvement over what other big pharma companies are doing to ensure access to their patented AIDS medicines in developing countries," said Michelle Childs, a director at Doctors Without Border's campaign for access to essential medicines. Still, she warned caution was necessary and that the new deal "should not become the template for future agreements."
Other major drugmakers including Johnson and Johnson, Abbott Laboratories and Merck & Co. have so far declined to formally negotiate with the U.N.-led group.
More information:
http://www.unitaid.eu
©2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
-
Patent fight in India centers on AIDS drug
May 11, 2006 |
not rated yet |
0
-
BRICS countries vow to help poor nations in health
Jul 11, 2011 |
not rated yet |
0
-
New study looks at long-term drug costs for treating AIDS in Brazil
Nov 13, 2007 |
not rated yet |
0
-
Brazil proves developing countries can use generic medicines to fight HIV/AIDS epidemic
Jul 14, 2009 |
not rated yet |
0
-
Poor countries to get new AIDS pill
Jul 06, 2006 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
'Gap' for HIV vaccine efforts after latest setback
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
HIV & AIDS
May 19, 2013 |
5 / 5 (1) |
0
AIDS science at 30: 'Cure' now part of lexicon
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
HIV & AIDS
May 18, 2013 |
5 / 5 (2) |
0
Peer-referral programs can increase HIV-testing in emergency departments
Researchers at the University of Cincinnati (UC) have found that incorporating a peer-referral program for HIV testing into emergency departments can reach new groups of high-risk patients and brings more patients into the ...
HIV & AIDS
May 17, 2013 |
not rated yet |
0
HIV no barrier to getting liver transplant, study finds
(HealthDay)—Liver transplants to treat a common type of liver cancer are a viable option for people infected with HIV, according to new research.
HIV & AIDS
May 17, 2013 |
not rated yet |
0
Twin epidemics: HIV and Hepatitis C in the urban Northeast
A new Yale study looks at the scope and consequences of a burgeoning health problem in the cities of the U.S. Northeast: concurrent infection with both HIV and Hepatitis C (HCV). The study appears online ...
HIV & AIDS
May 17, 2013 |
not rated yet |
0
Researchers find far-reaching, microvascular damage in uninjured side of brain after stroke
While the effects of acute stroke have been widely studied, brain damage during the subacute phase of stroke has been a neglected area of research. Now, a new study by the University of South Florida reports that within a ...
Digital divide exists with physician EHR adoption
(HealthDay)—The majority of physicians remain reluctant to adopt health information technology (HIT), according to a report by Deloitte Touche Tohmatsu.
Breakup of physician, drug company relationship could improve health care, cut cost
A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...
One in ten teens using 'study drugs,' but parents aren't paying attention
As high schoolers prepare for final exams, teens nationwide may be tempted to use a "study drug"—a prescription stimulant or amphetamine—to gain an academic edge. But a new University of Michigan poll shows only one in ...
Food laboratory accuracy remains a concern
Food microbiology laboratories continue to submit false negative results and false positive results on a routine basis. A retrospective study of nearly 40,000 proficiency test results over the past 14 years, presented today ...
Study supports 'aggressive' treatment for posterior fossa hematoma in newborns
Posterior fossa subdural hematoma (PFSDH) is a serious and rare condition in newborns, generally occurring after difficult deliveries. But with appropriate treatment, there's an excellent chance of good long-term outcomes ...